Rilonacept for Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS)
Clinical Trials - Muckle Wells, 2009-11-19 06:00:00

RESULTS AVAILABLE - Status: Completed, Condition Summary: Familial Cold Autoinflammatory Syndrome (FCAS); Familial Cold Urticaria; Muckle-Wells Syndrome (MWS); Genetic Diseases, Inborn

Efficacy and safety of rilonacept (interleukin-1 trap) in patients with cryopyrin-associated periodic syndromes: Results from two sequential placebo-controlled studies
Medworm: Muckle Wells, 2008-07-30 05:00:00

To assess the efficacy and safety of rilonacept (Interleukin-1 [IL-1] Trap), a long-acting and potent inhibitor of IL-1, in patients with cryopyrin-associated periodic syndromes (CAPS), including familial cold autoinflammatory syndrome (FCAS) and Muckle-Wells syndrome (MWS).

Rilonacept for Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS)
Clinical Trials - Muckle Wells, 2009-11-19 06:00:00

RESULTS AVAILABLE - Status: Completed, Condition Summary: Familial Cold Autoinflammatory Syndrome (FCAS); Familial Cold Urticaria; Muckle-Wells Syndrome (MWS); Genetic Diseases, Inborn

Improvement of Sensoneurinal Hearing Loss in a Patient with Muckle-Wells Syndrome Treated with Anakinra.
Recent scientific publications, 2010-02-04 01:00:00

Muckle Wells syndrome is an autoinflammatory disease in the group of cryopyrin associated periodic syndromes (CAPS). We report the case of an 8 year old girl with MWS who presented with remitting fever, urticaria, remitting coxitis, osteitis, bilateral uveitis anterior, elevated levels of C-reactive protein (CRP) and Serum amyloid A (SAA) and progressive sensoneurinal hearing loss. After starting treatment with anakinra, clinical symptoms dissolved almost completely for about two years now. 

Rilonacept for Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS)
Clinical Trials - Muckle Wells, 2009-11-19 06:00:00

RESULTS AVAILABLE - Status: Completed, Condition Summary: Familial Cold Autoinflammatory Syndrome (FCAS); Familial Cold Urticaria; Muckle-Wells Syndrome (MWS); Genetic Diseases, Inborn

Brain multiple sclerosis-like lesions in a patient with Muckle-Wells syndrome
Medworm: Muckle Wells, 2009-11-16 16:00:34

ARTICLE from Rheumotology (via MEDWORM). Muckle-Wells syndrome (MWS) is an autosomal dominant condition with variable penetrance characterized by recurrent fever syndromes, urticarial rash, non-exudative conjunctivitis, myalgia, arthralgia and/or arthritis, chronic headaches and/or increased intracranial pressure, chronic deafness and decreased level of energy [1]. MWS belongs to the group of cryopyrin-associated periodic fever (CAPS) including familial cold

Rilonacept for Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS)
Clinical Trials - Muckle Wells, 2009-11-19 06:00:00

RESULTS AVAILABLE - Status: Completed, Condition Summary: Familial Cold Autoinflammatory Syndrome (FCAS); Familial Cold Urticaria; Muckle-Wells Syndrome (MWS); Genetic Diseases, Inborn

Improvement of Sensoneurinal Hearing Loss in a Patient with Muckle-Wells Syndrome Treated with Anakinra.
Recent scientific publications, 2010-02-04 01:00:00

Muckle Wells syndrome is an autoinflammatory disease in the group of cryopyrin associated periodic syndromes (CAPS). We report the case of an 8 year old girl with MWS who presented with remitting fever, urticaria, remitting coxitis, osteitis, bilateral uveitis anterior, elevated levels of C-reactive protein (CRP) and Serum amyloid A (SAA) and progressive sensoneurinal hearing loss. After starting treatment with anakinra, clinical symptoms dissolved almost completely for about two years now. 

Novartis biological drug Ilaris® approved in EU to treat children and adults with CAPS
Meltwater News, 2009-11-01 18:36:21

The accelerated EU decision follows approvals in the US and Switzerland, where Ilaris was granted priority review in view of the significant unmet medical need. Ilaris is the only medicine approved in the EU for CAPS patients as young as four years old

Regeneron's Rilonacept Granted European Marketing Authorization for Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS)
Meltwater News, 2009-10-30 16:42:59

Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced it has received marketing authorization in the European Union for rilonacept, an interleukin-1 blocker, for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS) with severe symptoms, including Familial Cold Auto-inflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS), in adults and children aged 12 years and older